- Home
- THAR vs SNES Comparison
THAR vs SNES Comparison
Compare THAR & SNES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- SNES
- Stock Information
- Founded
- THAR 2017
- SNES 2004
- Country
- THAR United States
- SNES United States
- Employees
- THAR N/A
- SNES N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- SNES Agricultural Chemicals
- Sector
- THAR Health Care
- SNES Industrials
- Exchange
- THAR Nasdaq
- SNES Nasdaq
- Market Cap
- THAR 2.8M
- SNES 2.3M
- IPO Year
- THAR 2022
- SNES 2016
- Fundamental
- Price
- THAR $2.13
- SNES $3.20
- Analyst Decision
- THAR
- SNES Strong Buy
- Analyst Count
- THAR 0
- SNES 1
- Target Price
- THAR N/A
- SNES $10.00
- AVG Volume (30 Days)
- THAR 232.7K
- SNES 305.8K
- Earning Date
- THAR 11-07-2024
- SNES 11-12-2024
- Dividend Yield
- THAR N/A
- SNES N/A
- EPS Growth
- THAR N/A
- SNES N/A
- EPS
- THAR N/A
- SNES N/A
- Revenue
- THAR N/A
- SNES $1,651,000.00
- Revenue This Year
- THAR N/A
- SNES $91.45
- Revenue Next Year
- THAR N/A
- SNES $101.31
- P/E Ratio
- THAR N/A
- SNES N/A
- Revenue Growth
- THAR N/A
- SNES 38.16
- 52 Week Low
- THAR $1.84
- SNES $1.90
- 52 Week High
- THAR $8.55
- SNES $21.40
- Technical
- Relative Strength Index (RSI)
- THAR 46.63
- SNES 58.33
- Support Level
- THAR $2.09
- SNES $2.32
- Resistance Level
- THAR $2.27
- SNES $5.00
- Average True Range (ATR)
- THAR 0.17
- SNES 0.50
- MACD
- THAR -0.00
- SNES 0.14
- Stochastic Oscillator
- THAR 34.04
- SNES 39.16
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.